Zhi Fei Biological launches world’s first biological product for tuberculosis diagnosis

On May 11, Jiang Rensheng, chairman of Zhi Fei Biological, announced that new national class I drug of tuberculosis recombinant protein called Yika was officially launched to the market.

On May 11, Jiang Rensheng, chairman of Zhi Fei Biological, announced that new national class I drug of tuberculosis recombinant protein called Yika was officially launched to the market.

This is the first class I new drug in the TB prevention and treatment porfolio of Zhi Fei Biological.

It is reported that the “Yika®” project started in 2009 and completed Phase I, Phase II, and Phase III clinical trials in 2013, 2015, and 2018, respectively.

In the end, Zhi Fei Biological received the drug registration approval and drug approval number issued by the State Food and Drug Administration on April 28, 2020.

Yika® has become the world’s first biological product for tuberculosis diagnosis and tuberculosis infection diagnosis in nearly 100 years.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/12/zhi-fei-biological-launches-world-s-first-biological-product-for-tuberculosis-diagnosis/.

Leave a Reply

Please Login to Comment